ProQR Therapeutics (PRQR) Receivables (2022 - 2026)

ProQR Therapeutics (PRQR) posted Receivables of $5.5 million for Q1 2026, down 33.23% sequentially from $8.3 million in Q4 2025.

ProQR Therapeutics (PRQR) Receivables (2022 - 2026) Analysis & Trends

ProQR Therapeutics has reported Receivables for 4 years, with the latest figure at $5.5 million in Q1 2026.

Quarterly Receivables changed N/A year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (changed N/A YoY) and the FY2025 annual result came in at $8.3 million, up 69.1% from the prior year.
Receivables fell to $5.5 million in Q1 2026 per PRQR's latest filing, from $8.3 million in the prior quarter.
Over five years, Receivables peaked at $57.8 million in Q4 2022 and troughed at $4.9 million in Q4 2024.
A 4-year average of $19.1 million and a median of $6.9 million in 2026 frame the typical range for Receivables.
The widest YoY moves for Receivables: up 69.1% in 2025, down 69.1% in 2025.
Over 4 years, Receivables stood at $57.8 million in 2022, then tumbled by 91.53% to $4.9 million in 2024, then jumped by 69.1% to $8.3 million in 2025, then plunged by 33.23% to $5.5 million in 2026.
According to Business Quant data, Receivables over the past three periods registered $5.5 million, $8.3 million, and $4.9 million for Q1 2026, Q4 2025, and Q4 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.93 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.06 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	1.84 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	912.74 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	215.33 Mn
10	ProQR Therapeutics	206.80 Mn	111.86 Mn	-	5.53 Mn

Download Data